NCT05906524

KD6001 in Combination With Anti-PD-1 Antibody±Bevacizumab in Patients With Advanced HCC and Other Solid Tumors

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of KD6001 in Combination With Tislelizumab±Bevacizumab in Patients With Advanced HCC and Other Solid Tumors

• Status: Unknown
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 85 (estimated)
• Sponsor: Shanghai Kanda Biotechnology Co., Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a phase 1b/2, open label study to evaluate the safety, tolerability, pharmacokinetics and initial efficacy of KD6001 in combination with Tislelizumab ± Bevacizumab in patients with Advanced HCC and Other Solid Tumors.

Conditions

• Advanced HCC
• Other Solid Tumors

Interventions

Type	Name	Description
DRUG	KD6001	KD6001 will be administered intravenously.
DRUG	Tislelizumab	Tislelizumab will be administered intravenously.
DRUG	Bevacizumab	Bevacizumab will be administered intravenously.

Timeline

• Start date: 2024-04-15
• Primary completion: 2025-04-30
• Completion: 2025-12-31
• First posted: 2023-06-18
• Last updated: 2024-01-10

Locations

1 site across 1 country: China